Fibrinolytic agents present the only available pharmacotherapy able to dissolve a thrombus and open occluded vessels. Despite the worldwide experience with fibrinolytic therapy, there are limitations that must be considered.
As with all other management strategies for Acute Coronary Syndrome (ACS), contraindications for fibrinolytics in patients diagnosed with an ST-elevated myocardial infarction (STEMI) must be considered.
Discuss in detail the absolute and relative contraindications for fibrinolytic therapy in STEMI.
